199 related articles for article (PubMed ID: 35489768)
41. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract][Full Text] [Related]
42. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
43. Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis.
Chen Y; Wang S; Zhang B; Zhao Y; Zhang L; Hu M; Zhang W; Han B
Target Oncol; 2020 Jun; 15(3):337-345. PubMed ID: 32495159
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
Yi L; Fan J; Qian R; Luo P; Zhang J
Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
[TBL] [Abstract][Full Text] [Related]
45. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.
Schoenfeld AJ; Arbour KC; Rizvi H; Iqbal AN; Gadgeel SM; Girshman J; Kris MG; Riely GJ; Yu HA; Hellmann MD
Ann Oncol; 2019 May; 30(5):839-844. PubMed ID: 30847464
[TBL] [Abstract][Full Text] [Related]
46. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met.
Majem M; Sullivan I; Viteri S; López-Vivanco G; Cobo M; Sánchez JM; García-González J; Garde J; Sampayo M; Martrat G; Malfettone A; Karachaliou N; Molina-Vila MA; Rosell R
Eur J Cancer; 2021 Dec; 159():174-181. PubMed ID: 34763195
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
Wang X; Cai J; Zeng Z; Liu A
BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
[TBL] [Abstract][Full Text] [Related]
48. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
Wang C; Yu X; Wang W
Medicine (Baltimore); 2016 Dec; 95(52):e5539. PubMed ID: 28033249
[TBL] [Abstract][Full Text] [Related]
49. Impact of programmed death-ligand 1 expression on the patients of stage IV non-small cell lung cancer harboring epidermal growth factor receptor mutation: a systematic review and meta-analysis.
Lee CC; Soon YY; Leong CN; Koh WY; Tey J
Acta Oncol; 2020 Dec; 59(12):1430-1437. PubMed ID: 32835563
[TBL] [Abstract][Full Text] [Related]
50. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
51. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
52. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
[TBL] [Abstract][Full Text] [Related]
53. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
[TBL] [Abstract][Full Text] [Related]
54. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
[TBL] [Abstract][Full Text] [Related]
55. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.
Liao J; Huang Y; Gan J; Pang L; Ali WAS; Yang Y; Chen L; Zhang L; Fang W
Cancer Control; 2022; 29():10732748221081360. PubMed ID: 35201951
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.
Watanabe K; Yoh K; Hosomi Y; Usui K; Naka G; Kishi K; Uemura K; Ohashi Y; Kunitoh H
BMJ Open; 2022 Jan; 12(1):e046451. PubMed ID: 34983748
[TBL] [Abstract][Full Text] [Related]
58. The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis.
Lan B; Wang Y; Wu J; Wang K; Wang P
Medicine (Baltimore); 2021 Aug; 100(34):e27038. PubMed ID: 34449486
[TBL] [Abstract][Full Text] [Related]
59. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
60. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study.
Schmid S; Klingbiel D; Aeppli S; Britschgi C; Gautschi O; Pless M; Rothschild S; Wannesson L; Janthur W; Foerbs D; Demmer I; Jochum W; Früh M
Lung Cancer; 2019 Apr; 130():149-155. PubMed ID: 30885336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
